MAPT and Alzheimer disease: Translation of these findings into clinical trials, such as the development of MAPT ASO (BIIB080) for AD has yielded encouraging results, including a favorable safety profile in humans, significant CSF tau protein reduction (∼60%), and, remarkably, a reversal of pathological tau PET signal.128